ArticleRenal failure2025
Serum fibroblast growth factor 23 and kidney injury molecule-1 in the prediction of acute kidney injury in critically-ill patients.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic and prognostic value of fibroblast growth factor 23 in acute kidney injury: systematic review and meta-analysis.Renal failure · 2026Pooled it
- Early prediction of acute kidney injury after therapeutic paracentesis in decompensated liver cirrhosis: diagnostic value of IL-18, KIM-1, and FGF-23.Renal failure · 2026Article
- Transition from acute kidney injury to chronic kidney disease: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the value of serum intact fibroblast growth factor 23 (iFGF23), C-terminal FGF23 (cFGF23), and kidney injury molecule-1 (KIM-1) in predicting acute kidney injury (AKI) onset, severity, and renal function recovery in critically ill patients. A prospective cohort of 96 adults admitted to the intensive care unit (ICU) was analyzed. Patients were stratified into AKI (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.